Hubbry Logo
TirofibanTirofibanMain
Open search
Tirofiban
Community hub
Tirofiban
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Tirofiban
Tirofiban
Tirofiban
View on Wikipedia
from Wikipedia

Tirofiban
Clinical data
Trade namesAggrastat
AHFS/Drugs.comMonograph
MedlinePlusa601210
License data
Pregnancy
category
  • AU: B1
Routes of
administration		intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding65%
Elimination half-life2 hours
Identifiers
  • (2S)-2-[(butylsulfonyl)amino]-3-{4-[4-(piperidin-4-yl)butoxy]phenyl}propanoic acid
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.163.548 Edit this at Wikidata
Chemical and physical data
FormulaC22H36N2O5S
Molar mass440.60 g·mol−1
3D model (JSmol)
  • O=S(=O)(N[C@H](C(=O)O)Cc2ccc(OCCCCC1CCNCC1)cc2)CCCC
  • InChI=1S/C22H36N2O5S/c1-2-3-16-30(27,28)24-21(22(25)26)17-19-7-9-20(10-8-19)29-15-5-4-6-18-11-13-23-14-12-18/h7-10,18,21,23-24H,2-6,11-17H2,1H3,(H,25,26)/t21-/m0/s1 checkY
  • Key:COKMIXFXJJXBQG-NRFANRHFSA-N checkY
  (verify)

Tirofiban, sold under the brand name Aggrastat, is an antiplatelet medication. It belongs to a class of antiplatelets named glycoprotein IIb/IIIa inhibitors. Tirofiban is a small molecule inhibitor of the protein-protein interaction between fibrinogen and the platelet integrin receptor GP IIb/IIIa and is the first drug candidate whose origins can be traced to a pharmacophore-based virtual screening lead.[2][3]

It is available as a generic medication.[4]

Medical uses

[edit]

Tirofiban is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in people with non-ST elevation acute coronary syndrome.[1]

Contraindications and precautions

[edit]

Tirofiban is contraindicated in patients with:

Adverse reactions

[edit]

Bleeding is the most commonly reported adverse reaction.[5]

Use in pregnancy

[edit]

Tirofiban has been demonstrated to cross the placenta in pregnant rats and rabbits. Although the doses employed in these studies were a multiple of those used in human beings. no adverse effects on the offspring in both animals have been seen. However, there are no adequate and well controlled studies in pregnant women. Therefore, tirofiban should be used during pregnancy only if clearly indicated.

Nursing mothers: It is not known whether tirofiban is excreted in human milk. However, significant levels of tirofiban are excreted in rat milk. Therefore, nursing should be discontinued during the period of drug administration and the milk discarded. Nursing may resume 24 hours after cessation of treatment with tirofiban.

Pediatric use

[edit]

Safety and effectiveness in children have not been established.

Other precautions and laboratory exams

[edit]

The activated partial thromboplastin time is the most reliable coagulation parameter and should be obtained regularly during treatment, particular if a bleeding episode occurs that may be associated with tirofiban therapy. Other important hematological parameters are platelet count, clotting time, hematocrit and hemoglobin. Proper technique regarding artery site access for sheath placement and removal of sheath should be followed. Arterial sheaths should be removed when the patient's activated clotting time is < 180 seconds or 2 to 6 hours following withdrawal of heparin.

Side effects

[edit]

The following side effects were noted under treatment with tirofiban and heparin (and aspirin, if tolerated). Other drugs were used as necessary.

The major adverse effect is bleeding on local sites of clinical intervention and systemically (regarding parts of the body or the whole body system). Major bleeding has occurred in 1.4% of patients and minor bleeding in 10.5%. Transfusions were required to terminate bleeding and to improve bleeding-related anemia in 4.0% of all patients. Geriatric patients have experienced more bleeding episodes than younger, women more than men.

Thrombocytopenia was more often seen in the tirofiban + heparin group (1.5%) than in the heparin control group (0.8%). This adverse effect was usually readily reversible within days.

Positive fecal and urine hemoglobin tests have also been reported.

Post-marketing events have been the occurrence of intracranial bleeding, retroperitoneal bleeding, pulmonary hemorrhage and spinal-epidural hematoma. Fatal bleeding have been reported rarely.

Sometimes, thrombocytopenia was associated with chills, low-grade fever or bleeding complications (see above).

Cases of hypersensitivity including anaphylaxis have occurred.

Interactions

[edit]

The concomitant application of warfarin or other oral anticoagulants may increase the risk of serious bleeding events. The decision whether maintenance therapy with these drugs should be discontinued during tirofiban treatment has to be made by the responsible clinician.

Pharmacology

[edit]

Tirofiban has a rapid onset and short duration of action after proper IV administration. Coagulation parameters turn to normal 4 to 8 hours after the drug is withdrawn.

Chemistry

[edit]

Tirofiban is a synthetic, non-peptide inhibitor of the interaction of fibrinogen with the integrin glycoprotein IIb/IIIa on human platelets. The Merck chemistry team of George Hartman, Melissa Egbertson and Wasyl Halczenko developed tirofiban from a lead compound discovered in focused screening of small molecule replacements of the key arginine-glycine-aspartic acid (Arg-Gly-Asp) subunit of fibrinogen. Computation of the distance between the charged Arg and Asp sites in fibrinogen provided guidance leading to directed screening success. Tirofiban constitutes an antithrombotic, specifically an inhibitor of platelet aggregation.

Tirofiban is a modified version of a molecule found in the venom of the saw-scaled viper Echis carinatus.[6][7]

History

[edit]

The drug is marketed under the brand name Aggrastat in the US by Medicure Pharma, in China by Eddingpharm, and in the rest of the world by Correvio International Sàrl.

According to the US Orange Book, it was first approved in the US on 20 April 2000. Patent numbers 5733919; 5965581 and 5972967 all expired in October 2016. Patent 5978698 expired in October 2017. Patent 6136794 expired in January 2019. Patent 6770660 expires in June 2023.

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Tirofiban

View on Grokipedia
from Grokipedia
Tirofiban is a non-peptide, reversible of the platelet (GP IIb/IIIa) receptor, administered intravenously as tirofiban hydrochloride to inhibit platelet aggregation and reduce the risk of thrombotic events in patients with non-ST elevation (NSTE-ACS). Marketed under the brand name Aggrastat, it was approved by the U.S. on May 14, 1998, for use in combination with and aspirin to decrease the incidence of death, , or refractory ischemia/repeat coronary . Tirofiban functions by competitively binding to the GP IIb/IIIa receptor, the final common pathway for platelet aggregation, thereby preventing fibrinogen from cross-linking platelets and inhibiting (ADP)-induced aggregation by over 90% within 10 minutes of administration at recommended doses. Its elimination is approximately 2 hours, with platelet function returning to near baseline within 4 to 8 hours after discontinuation. Clinical trials such as PRISM-PLUS, involving 1,915 patients with or non-Q-wave , showed that tirofiban plus reduced the 7-day composite risk of death, , and refractory ischemia by 32% compared to alone, with sustained benefits at 30 days (22% risk reduction) and 6 months (19% risk reduction). Similarly, the RESTORE trial in high-risk patients undergoing demonstrated a 38% reduction in ischemic complications at 2 days and 27% at 7 days when tirofiban was added to . Recent studies as of 2025 have also shown benefits in acute ischemic , with early tirofiban infusion after improving disability-free outcomes. The standard dosing regimen consists of an initial bolus of 25 mcg/kg administered intravenously over 5 minutes, followed by a of 0.15 mcg/kg/min for up to 18 hours; dosage adjustments to 0.075 mcg/kg/min are required for patients with clearance ≤60 mL/min. Chemically, tirofiban has the molecular formula C₂₂H₃₆N₂O₅S and a molecular weight of 440.6 g/mol, existing as a white to off-white, non-hygroscopic powder in its monohydrate form. The most notable adverse effects include bleeding complications and , occurring at rates similar to or slightly higher than comparator therapies, with contraindications for active , history of , or prior tirofiban-induced .

Clinical Use

Indications

Tirofiban is indicated for the reduction of thrombotic cardiovascular events, including death, , or refractory ischemia requiring repeat cardiac procedures, in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). This encompasses both and non-ST-elevation (NSTEMI), where it serves as an adjunctive antiplatelet therapy to prevent acute ischemic complications in high-risk patients. As a reversible inhibitor, tirofiban inhibits platelet aggregation to mitigate formation in these scenarios. In clinical practice, tirofiban is approved for use in NSTE-ACS patients managed medically as well as those undergoing (PCI), where it reduces periprocedural thrombotic risks such as abrupt vessel closure or stent thrombosis. It is typically administered in combination with aspirin and an such as unfractionated or to enhance effects, based on evidence from pivotal trials demonstrating improved outcomes with this regimen. Patient selection prioritizes those with high-risk features, including ongoing or recurrent ischemia, elevated cardiac levels, or dynamic electrocardiographic changes such as ST-segment depression, as these indicate a greater likelihood of benefit from intensified antiplatelet therapy per ACC/AHA guidelines. Although not FDA-approved for this purpose, emerging evidence supports investigational use of tirofiban in acute ischemic stroke, particularly as bridge or adjunct to intravenous and endovascular in select patients to improve recanalization and functional outcomes. For instance, the ASSET-IT trial, published in 2025, demonstrated that adding intravenous tirofiban to improved 90-day scores in patients treated within 4.5 hours of symptom onset, with an acceptable safety profile regarding hemorrhagic transformation. Such applications remain off-label and are supported by recent completed clinical trials evaluating efficacy in settings such as and endovascular .

Dosage and Administration

Tirofiban is administered intravenously for the management of non-ST-elevation (NSTE-ACS). The standard regimen consists of a of 25 mcg/kg infused over 5 minutes, followed by a of 0.15 mcg/kg/min for up to 18 hours. Dosage adjustments are required for patients with renal impairment. For those with clearance (CrCl) ≤ 60 mL/min, the remains 25 mcg/kg over 5 minutes, but the is reduced to 0.075 mcg/kg/min for up to 18 hours; CrCl should be calculated using the Cockcroft-Gault formula with actual body weight. No dosage adjustment is necessary for hepatic impairment, as tirofiban is primarily renally excreted. Tirofiban is for intravenous use only and is available in formulations suitable for bolus administration via syringe or IV pump and for continuous . It is compatible with common intravenous fluids such as 0.9% normal saline and 5% dextrose in water (D5W), as well as co-administration with , atropine, , and in the same IV line. The drug should be inspected for particulates and discoloration prior to use, and unused portions discarded after withdrawal. The duration of is typically up to 18 hours, initiated as soon as possible after in NSTE-ACS patients, with continuation through (PCI) if performed. Monitoring includes assessment of renal function prior to to guide dosing and periodic during if renal status changes. Platelet counts should be monitored starting approximately 6 hours after and daily thereafter to detect . Platelet function testing is not routinely required. Discontinuation of tirofiban does not require tapering, as its effects are rapidly reversible due to a plasma of approximately 2 hours; platelet function typically returns to near baseline within 4 to 8 hours after stopping the .

Safety Profile

Contraindications

Tirofiban, a receptor inhibitor, carries significant risks due to its potent antiplatelet effects, necessitating strict contraindications to avoid life-threatening hemorrhage in high-risk patients. Absolute contraindications include conditions where the potential for severe bleeding outweighs any therapeutic benefit. Absolute contraindications:
  • Active internal bleeding or history of bleeding diathesis: Tirofiban is contraindicated in patients with ongoing hemorrhage or inherent clotting disorders, as its inhibition of platelet aggregation can exacerbate at any site, including gastrointestinal or genitourinary tracts.
  • History of or recent (within 30 days): Prior intracranial bleeding or any stroke in the recent month increases the risk of recurrent hemorrhagic events, given tirofiban's role in disrupting in vulnerable cerebral vasculature.
  • Major or severe physical trauma (within 30 days): Recent invasive procedures or injuries heighten bleeding potential at surgical sites or fracture areas due to impaired platelet function induced by tirofiban.
  • Severe uncontrolled (systolic >180 mmHg or diastolic >110 mmHg): Elevated promotes vascular fragility and rupture, compounding tirofiban's antithrombotic effects to cause catastrophic intracranial or systemic bleeds.
  • (platelet count <100,000/mm³) or history of thrombocytopenia with prior tirofiban exposure: Low baseline platelets or prior drug-induced drops amplify hemorrhage risk, as tirofiban can further suppress platelet counts through immune-mediated mechanisms.
  • Known hypersensitivity to tirofiban: Allergic reactions, including anaphylaxis, preclude use to prevent severe adverse events unrelated to bleeding.
Relative contraindications involve scenarios where tirofiban may be used with extreme caution and close monitoring, but is generally avoided due to elevated harm potential:
  • Recent gastrointestinal bleeding (within 3 months): Prior upper or lower GI hemorrhage signals mucosal vulnerability, where tirofiban's antiplatelet action could provoke rebleeding, though some guidelines extend caution to 1 year.
  • Concurrent use of other glycoprotein IIb/IIIa inhibitors: Overlapping antiplatelet therapy intensifies inhibition of platelet function, leading to profound bleeding risks without additive clinical benefit.
  • Planned puncture at a non-compressible site: Procedures like femoral artery access without compression capability heighten uncontrollable bleeding odds in the context of tirofiban's effects.
  • Active peptic ulcer disease: Ongoing gastric or duodenal ulceration represents a focal bleeding source that tirofiban could worsen through reduced clot formation.
These contraindications stem primarily from tirofiban's mechanism, which reversibly binds platelet receptors to prevent fibrinogen-mediated aggregation, thereby impairing primary hemostasis and increasing susceptibility to bleeding complications observed in clinical trials and post-marketing data.

Warnings and Precautions

Tirofiban therapy requires careful management to mitigate bleeding risks, as hemorrhage is the most common complication associated with its use, particularly at arterial access sites during cardiac catheterization. To reduce this risk, healthcare providers should minimize the number of arterial and venous punctures, intramuscular injections, and other potentially traumatic procedures. In patients undergoing percutaneous coronary intervention (PCI), the use of the smallest feasible arterial sheath size is recommended to further limit bleeding potential. Additionally, patients should be monitored for signs of hemorrhage through regular assessments of hemoglobin and hematocrit levels, with immediate discontinuation of tirofiban if bleeding cannot be controlled by conservative measures. Patients with renal impairment necessitate dose adjustments and enhanced monitoring to prevent drug accumulation. For those with creatinine clearance (CrCl) ≤ 60 mL/min, the maintenance infusion rate should be reduced to 0.075 mcg/kg/min following the standard loading dose, as plasma clearance of is decreased by approximately 40% to 50% in such individuals. Closer surveillance of renal function is advised throughout therapy to ensure appropriate dosing and to detect any worsening impairment that could exacerbate bleeding risks. Elderly patients face a heightened risk of bleeding when treated with tirofiban, owing to age-related declines in renal function and other physiological changes. Although no routine dose adjustment is required for this population, initiation with a lower dose may be considered in high-risk cases to balance efficacy and safety, with vigilant monitoring for hemorrhagic events. Routine laboratory monitoring is essential for safe tirofiban administration. Baseline assessments should include platelet counts, coagulation parameters such as prothrombin time (PT) and activated partial thromboplastin time (aPTT)—particularly when coadministered with heparin—and renal function tests. Platelet counts should be checked approximately 6 hours after initiation and daily thereafter; if counts fall below 90,000/mm³, pseudothrombocytopenia must be ruled out, and tirofiban along with heparin discontinued if true thrombocytopenia is confirmed. Periodic evaluations of hemoglobin, hematocrit, and renal function are also recommended to detect early signs of bleeding or accumulation. Re-administration of tirofiban carries an increased risk of immune-mediated thrombocytopenia, especially in patients with prior exposure to glycoprotein IIb/IIIa inhibitors. Close monitoring of platelet counts is critical upon re-exposure, with immediate evaluation and potential discontinuation if thrombocytopenia develops. Caution is advised in patients with aortic dissection or severe liver disease, where tirofiban use should be avoided if possible due to potential exacerbation of bleeding risks, although it is not an absolute contraindication in all cases. Brief reference to active bleeding as a contraindication underscores the need for thorough patient screening prior to initiation.

Adverse Effects

Common Adverse Effects

The most common adverse effects of tirofiban, occurring in more than 1% of patients, are related to its antiplatelet activity and include minor bleeding and thrombocytopenia. In the PRISM-PLUS trial, minor bleeding—defined by TIMI criteria as spontaneous gross hematuria, hemoglobin drop greater than 3 g/dL without an identified source, or other minor manifestations such as petechiae or ecchymosis without hemodynamic instability—occurred in 10.5% of patients receiving tirofiban plus heparin compared to 8.0% with heparin alone. Examples of minor bleeding include hematuria and gingival bleeding, which typically peak during infusion and resolve upon discontinuation without intervention. Across clinical studies, minor bleeding rates range from 11% to 15%. Thrombocytopenia, characterized by a platelet count below 90,000/mm³, affects 1% to 4% of patients and is usually reversible after stopping the drug. In PRISM-PLUS, the incidence was 1.5% in the tirofiban group versus 0.6% in controls, with onset often within hours of initiation. Other frequent effects include nausea (2% to 5%), headache (approximately 3%), dizziness (2% to 3%), and hypotension (1% to 2%), which are generally mild and self-limiting. In PRISM-PLUS, dizziness was reported in 3% of tirofiban-treated patients compared to 2% in the heparin group. Tirofiban's mechanism of action, which involves reversible antagonism of the platelet glycoprotein IIb/IIIa receptor, underlies the increased bleeding risk by preventing fibrinogen binding and subsequent platelet aggregation. Most adverse effects resolve post-discontinuation, with bleeding events most prominent during the infusion period.

Serious Adverse Effects

Tirofiban, a glycoprotein IIb/IIIa inhibitor, is associated with serious adverse effects primarily involving hemorrhagic complications and hematologic disturbances. Major bleeding events, defined by criteria such as a hemoglobin drop greater than 5 g/dL or intracranial hemorrhage, occur in approximately 1-2% of patients undergoing percutaneous coronary intervention (PCI), with higher rates observed in combination with and . Specific severe forms include intracranial hemorrhage, reported at 0.02-0.1% overall and 0.1% in the RESTORE trial (1/1071 patients on tirofiban), and retroperitoneal bleeding at 0.1-0.5% or 0.6% in RESTORE (6/1071). The RESTORE trial demonstrated an increased incidence of TIMI major bleeding with tirofiban (2.4%) compared to placebo (2.1%), particularly post-procedure. Acute profound thrombocytopenia, characterized by platelet counts below 20,000/mm³, affects 0.3-1% of patients and is often immune-mediated due to drug-dependent antibodies. In clinical trials like PRISM-PLUS, severe thrombocytopenia (below 50,000/mm³) occurred in 0.3% with tirofiban plus heparin versus 0.1% with heparin alone, while RESTORE reported 0.2% severe cases (below 50,000/mm³). This condition can manifest rapidly within hours of infusion and increases bleeding risk. Other severe effects include anaphylactic reactions, occurring in less than 0.01% based on post-marketing reports, bradycardia in about 1% of cases, and cholesterol embolization during PCI procedures, a rare procedural complication not uniquely tied to tirofiban but exacerbated by antiplatelet therapy. Management of major bleeding requires immediate discontinuation of tirofiban and supportive measures to control hemorrhage. For severe thrombocytopenia, prompt cessation of tirofiban and , along with platelet transfusion, is recommended to mitigate thrombotic and bleeding risks. Anaphylaxis demands supportive care, including epinephrine and airway management. Platelet monitoring every 2-6 hours post-initiation is essential to detect these effects early.

Effects in Special Populations

Tirofiban is classified as FDA Pregnancy Category B, indicating no evidence of risk to the fetus in animal reproduction studies, with doses up to 5 mg/kg/day showing no fetal harm in rats and rabbits, though human data are limited. No definitive association has been found between tirofiban exposure and major birth defects or miscarriage in available human reports, including case studies where it was used without adverse maternal, fetal, or neonatal events; however, its antiplatelet effects raise concerns for potential fetal bleeding risks, particularly during delivery. Use during pregnancy is recommended only if the potential benefit justifies the risk, especially in life-threatening maternal conditions like acute myocardial infarction, where untreated disease poses significant risks to both mother and fetus. Regarding lactation, there are no data on tirofiban's presence in human breast milk, though it is excreted in rat milk, and its effects on breastfed infants remain unknown. Clinicians should weigh the benefits of breastfeeding against potential risks to the infant, with discontinuation of nursing often advised during and shortly after tirofiban therapy. Tirofiban is not approved for pediatric use, and its safety and efficacy have not been established in patients under 18 years. Limited case reports describe off-label applications in pediatric settings, such as preventing thrombosis in congenital heart disease surgeries or managing acute ischemic stroke and procedural complications, with generally favorable outcomes but without systematic data to support routine use. In elderly patients over 65 years, who comprised 43% of participants in clinical trials, tirofiban's efficacy is comparable to that in younger adults, but bleeding risk is elevated, potentially 1.5 to 2 times higher due to age-related factors. No dosage adjustments are required, though enhanced monitoring for hemorrhagic events is essential. For patients with renal impairment, tirofiban's plasma clearance decreases by approximately 40% in those with creatinine clearance (CrCl) below 60 mL/min and over 50% below 30 mL/min, necessitating a reduced maintenance infusion rate of 0.075 mcg/kg/min after the standard bolus to mitigate bleeding risks. Its use is not recommended in end-stage renal disease patients on hemodialysis, as safety and efficacy data are lacking. In hepatic impairment, no dosage modifications are needed, as liver function does not significantly affect tirofiban clearance.

Drug Interactions

Pharmacokinetic Interactions

Tirofiban is administered exclusively via intravenous infusion, eliminating the possibility of pharmacokinetic interactions involving gastrointestinal absorption or oral bioavailability. The drug demonstrates low plasma protein binding, with approximately 65% bound to proteins and an unbound fraction of 35% across clinically relevant concentrations (0.01–25 µg/mL); this characteristic reduces the likelihood of significant displacement interactions with highly protein-bound agents, such as . Metabolism of tirofiban is minimal, with no substantial involvement of cytochrome P450 enzymes, and the majority of the administered dose—about 65%—is excreted unchanged in the urine, while approximately 25% appears in feces, also largely unchanged. Renal clearance accounts for 39–69% of total plasma clearance, which ranges from 213–314 mL/min in healthy individuals and 152–267 mL/min in patients with coronary artery disease. Given its predominant renal elimination pathway, tirofiban's pharmacokinetics are notably altered in renal impairment, where plasma clearance decreases by about 40% in patients with creatinine clearance (CrCl) <60 mL/min and by more than 50% in those with CrCl <30 mL/min, resulting in a prolongation of the elimination half-life (normally ~2 hours) by roughly 1.7-fold to over 2-fold in severe cases. Tirofiban is dialyzable, supporting its removal via hemodialysis in renal failure. Clinical evaluations, including subsets from the PRISM study (n=762), indicate no clinically significant pharmacokinetic interactions affecting tirofiban clearance upon coadministration with commonly used cardiovascular agents, such as aspirin, heparin, acebutolol, acetaminophen, atropine, dobutamine, dopamine, epinephrine, furosemide, lidocaine, midazolam, morphine, nitroglycerin, potassium chloride, or propranolol. Minor variations in clearance were noted with or , but their clinical relevance remains undetermined. Overall, data on potential interactions with renal secretion inhibitors like or other nephrotoxic agents such as certain nonsteroidal anti-inflammatory drugs (beyond aspirin) are limited, with no dedicated interaction trials reported; however, agents impairing renal function may indirectly prolong tirofiban's half-life, warranting monitoring in combination therapy.

Pharmacodynamic Interactions

Tirofiban, a glycoprotein IIb/IIIa receptor antagonist that reversibly inhibits platelet aggregation by preventing fibrinogen binding, exhibits pharmacodynamic interactions primarily through additive effects on hemostasis when combined with other antithrombotic agents. These interactions enhance the risk of bleeding by further impairing platelet function or coagulation, necessitating careful monitoring and potential adjustments in therapy. Concomitant use with anticoagulants such as heparin, enoxaparin, or bivalirudin results in additive bleeding risks due to synergistic inhibition of thrombus formation. For patients receiving heparin, activated partial thromboplastin time (aPTT) should be monitored 6 hours after initiation and adjusted to approximately 2 times control to mitigate excessive anticoagulation. In the PRISM-PLUS trial, tirofiban combined with heparin and aspirin increased major bleeding incidence to 1.4% compared to 0.8% with heparin alone, though it reduced composite ischemic events by 32%. Interactions with other antiplatelet agents amplify platelet inhibition and bleeding potential. Aspirin, when used with tirofiban, heightens the antiplatelet effect through complementary pathways, as evidenced by increased minor bleeding rates (10.5% vs. 8.0%) in PRISM-PLUS trial participants. Concomitant use with other antiplatelet agents such as clopidogrel and prasugrel may further amplify these effects based on their complementary mechanisms of action. Concurrent administration with other glycoprotein IIb/IIIa inhibitors like abciximab is not recommended due to risks of profound thrombocytopenia and excessive inhibition, with studies showing further declines in platelet function upon overlap. Concomitant use of fibrinolytics such as tissue plasminogen activator (tPA) or streptokinase with tirofiban increases the risk of hemorrhage from combined thrombolytic and antiplatelet actions and should be used with caution. The FDA prescribing information highlights that coadministration of fibrinolytics with tirofiban and other antithrombotics increases bleeding complications. Nonsteroidal anti-inflammatory drugs (NSAIDs) and selective serotonin reuptake inhibitors (SSRIs) cause mild potentiation of bleeding via indirect platelet dysfunction, with moderate severity interactions reported. Management involves monitoring for signs of hemorrhage, particularly in patients with additional risk factors. In percutaneous coronary intervention (PCI) settings, dose reductions of tirofiban (e.g., maintenance infusion to 0.075 mcg/kg/min in renal impairment) or timing adjustments with anticoagulants and antiplatelets are recommended to balance efficacy and bleeding risks, supported by trial data analogous to PRISM-PLUS showing improved outcomes with optimized regimens.

Pharmacology

Mechanism of Action

Tirofiban is a reversible non-peptide antagonist that selectively targets the glycoprotein IIb/IIIa (αIIbβ3) receptors on the surface of platelets. These receptors, also known as αIIbβ3, play a critical role in the final common pathway of platelet aggregation by facilitating the binding of adhesive proteins such as fibrinogen and . By competitively binding to the receptor's fibrinogen-binding site, tirofiban prevents these ligands from attaching, thereby inhibiting the cross-linking of platelets and subsequent formation. This mechanism effectively blocks platelet aggregation triggered by multiple agonists, including (ADP), , and , which activate upstream signaling pathways leading to receptor exposure and conformational change. Tirofiban demonstrates high potency, with an IC50 of approximately 10 nM for inhibiting fibrinogen binding to activated platelets . Intravenous administration results in rapid onset, achieving over 90% inhibition of ADP-induced platelet aggregation within 5 to 10 minutes and nearing 100% at peak effect during infusion. The drug's reversibility stems from its short plasma half-life of about 2 hours, allowing platelet aggregation to recover to near baseline levels within 4 to 8 hours following infusion cessation in most patients. As a small-molecule non-peptide (molecular weight ~441 Da), tirofiban is less immunogenic compared to abciximab, a larger Fab fragment of a (~48 kDa) that can elicit responses. This distinction contributes to tirofiban's favorable profile for short-term use in acute settings.

Pharmacokinetics

Tirofiban is administered intravenously, resulting in immediate and complete of approximately 100%. Following intravenous administration, tirofiban exhibits a steady-state ranging from 22 to 42 L, indicating moderate distribution into . The drug is moderately bound to plasma proteins, with approximately 65% binding that is independent of concentration over the range of 0.01 to 25 µg/mL. have demonstrated that tirofiban crosses the in pregnant rats and rabbits. Tirofiban undergoes minimal hepatic metabolism, with no active metabolites identified. Elimination of tirofiban occurs primarily via renal excretion, with about 65% of the administered dose recovered unchanged in the urine and approximately 25% in the feces. The elimination half-life is approximately 2 hours in individuals with normal renal function but is prolonged in patients with renal impairment, with plasma clearance reduced by about 40% in patients with creatinine clearance less than 60 mL/min and by more than 50% when less than 30 mL/min. Plasma clearance in healthy subjects ranges from 213 to 314 mL/min, with renal clearance accounting for 39% to 69% of total plasma clearance; clearance is reduced by about 40% in patients with creatinine clearance less than 60 mL/min and by more than 50% when less than 30 mL/min. As an intravenous agent, tirofiban is unaffected by food intake, and steady-state plasma concentrations are achieved during continuous infusion. Dosing adjustments are recommended for patients with renal impairment to account for decreased clearance.

Chemistry

Molecular Structure

Tirofiban is a synthetic non-peptide compound with the IUPAC name (2S)-2-(butylsulfonylamino)-3-[4-[4-(piperidin-4-yl)butoxy]phenyl]propanoic acid. The molecular formula of the free base is C22H36N2O5S, while the clinically used monohydrate form has the formula C22H36N2O5S • HCl • H2O. Structurally, tirofiban functions as a mimetic of the arginine-glycine-aspartic acid (RGD) sequence found in fibrinogen, designed to antagonize platelet receptors. It is derived from L-tyrosine, where the amino group is substituted with a butylsulfonyl moiety, and the phenolic hydroxyl is extended via an ether linkage to a 4-(piperidin-4-yl)butyl chain, which incorporates a piperidine ring critical for receptor interaction. The molecule's key functional groups include the sulfonamide at the N-terminus, the carboxylic acid at the C-terminus, and the basic piperidine nitrogen, contributing to its selectivity for glycoprotein IIb/IIIa binding. Tirofiban exhibits specific at the α-carbon, with the active S-enantiomer corresponding to the natural configuration, which is essential for its biological potency. The standard two-dimensional representation of tirofiban's structure highlights the central core flanked by the sulfonyl and piperidine-substituted alkyl chains, with the group absent as it is not part of this molecule's architecture.

Physical Properties

Tirofiban is formulated as the monohydrate salt and supplied as a clear, colorless, sterile, non-pyrogenic solution for intravenous use, available in concentrations of 50 mcg/mL in 100 mL or 250 mL single-dose containers and 250 mcg/mL in 5 mL or 50 mL single-dose vials. The formulation contains no preservatives and includes , dihydrate, anhydrous, and water for injection, with the pH adjusted to 5.5–6.5 using and/or . The monohydrate form appears as a to off- powder that is very slightly soluble in but sufficiently soluble to support the low concentrations used in the injectable (up to 0.25 mg/mL). Tirofiban solutions are stable at , with recommended storage at 25°C (77°F) and excursions permitted to 15–30°C (59–86°F); freezing must be avoided, and the product is light-sensitive, requiring protection from light during storage and handling. The drug is compatible for administration via PVC or bags and tubing. The pKa values are approximately 3.3 for the carboxylic acid group and 10.5 for the amine group, reflecting its zwitterionic nature in neutral pH ranges. The computed logP is around 0.6 to 1.8, indicating hydrophilic character consistent with its aqueous formulation.

History

Development

Tirofiban was developed by Merck & Co. in the early 1990s as a synthetic, non-peptide inhibitor of the glycoprotein IIb/IIIa (GP IIb/IIIa) receptor on platelets, designed to mimic the arginine-glycine-aspartic acid (RGD) sequence found in disintegrins like echistatin from snake venom. The compound evolved from lead structures identified through focused screening efforts by Merck's chemistry team, aiming for rapid, reversible antagonism to provide potent antiplatelet effects with a favorable safety profile compared to earlier agents like abciximab. This focus on reversibility distinguished tirofiban, as its competitive binding allows quick recovery of platelet function upon discontinuation, unlike the prolonged binding of monoclonal antibody-based inhibitors. Preclinical studies demonstrated tirofiban's efficacy in inhibiting platelet aggregation. assays showed it potently blocked ADP-induced platelet aggregation with an of approximately 9 nM in gel-filtered human platelets. Animal models, including canine arteriovenous shunt systems, confirmed its ability to prevent and without excessive at therapeutic doses, while studies in rats and dogs established safe pharmacokinetic profiles for intravenous administration. These findings supported advancement to clinical testing, highlighting tirofiban's selectivity for activated platelets and minimal impact on other . Key phase III trials validated tirofiban's clinical utility in the late 1990s. The RESTORE trial, completed in 1997, enrolled 2,139 patients undergoing high-risk and showed that tirofiban reduced the composite endpoint of death, , or target vessel revascularization by 38% at 2 days, 27% at 7 days, and 16% at 30 days compared to . The trial in 1998 randomized 3,232 patients with or non-Q-wave to tirofiban or , demonstrating a 32% reduction in death, , or refractory ischemia at 48 hours. Building on this, the PRISM-PLUS trial confirmed that combining tirofiban with reduced the 7-day composite endpoint of death, , or refractory ischemia by 32% and death or by 27% at 30 days versus alone. Development milestones included successful phase III outcomes in 1997, paving the way for regulatory submission, with emphasis on tirofiban's reversible binding kinetics to mitigate prolonged risks associated with . After initial development, marketing rights were transferred from Merck to MGI Pharma in 2003 and later to Medicure in 2006. Early challenges involved balancing efficacy against bleeding risks; initial dosing in the trial was adjusted via protocol amendment to optimize platelet inhibition while reducing major bleeding incidences, which were comparable to in final analyses.

Regulatory Approvals

Tirofiban, marketed under the brand name Aggrastat by Merck & Co., received initial approval from the U.S. Food and Drug Administration (FDA) on May 14, 1998, for use in combination with heparin to reduce the rate of thrombotic cardiovascular events in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), including those managed medically and those undergoing percutaneous coronary intervention (PCI). In 1999, the FDA approved a supplemental new drug application expanding its indications to include specific use as an adjunct to PCI for the prevention of thrombotic complications. The (EMA) granted marketing authorization for tirofiban on June 18, 1999, for the prevention of early in patients with or non-Q-wave , with similar extensions for use in PCI. Approvals followed in other regions, including on September 20, 1999, for the management of and on April 29, 1999, for acute coronary syndromes. Label updates have refined tirofiban's use over time. In 2005, the FDA adjusted dosing recommendations for patients with renal impairment to account for reduced clearance in those with clearance below 60 mL/min, recommending a 50% dose reduction to mitigate bleeding risks. A significant revision occurred in October 2013, when the FDA approved a high-dose bolus regimen (25 mcg/kg over 3 minutes followed by a 0.15 mcg/kg/min infusion for up to 18 hours) to support shorter infusion durations in NSTE-ACS and PCI settings, based on data from the PRISM-PLUS and TARGET trials. Generics have entered the market since the following expiration of key patents starting in 2016, with the last relevant patent expiring in 2023; the first U.S. generic approvals for tirofiban injection occurred in 2020. Post-marketing surveillance has focused on , a known occurring in up to 1.5% of patients, with recommendations for platelet monitoring during and after ; no major safety issues have led to withdrawals from the market. In the 2020s, clinical trials have explored tirofiban's potential in acute ischemic , such as the ASSET-IT trial showing improved outcomes when added to , but no new regulatory approvals for this indication have been granted as of November 2025.

References

  1. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20912ltr.pdf
  2. https://pubmed.ncbi.nlm.nih.gov/9878994/
  3. https://www.nejm.org/doi/full/10.1056/NEJMoa2503678
  4. https://pubchem.ncbi.nlm.nih.gov/compound/Tirofiban
  5. https://reference.medscape.com/drug/aggrastat-tirofiban-342185
  6. https://go.drugbank.com/drugs/DB00775
  7. https://www.ahajournals.org/doi/10.1161/cir.0000000000000134
  8. https://www.jacc.org/doi/10.1016/j.jacc.2014.09.016
  9. https://www.tctmd.com/news/asset-it-tirofiban-boosts-outcomes-after-iv-thrombolysis-acute-stroke
  10. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2832908
  11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020912s027%2C020913s026lbl.pdf
  12. https://www.thecardiologyadvisor.com/ddi/glycoprotein-iib-iiia-inhibitors/
  13. https://www.drugguide.com/ddo/view/Davis-Drug-Guide/51747/all/tirofiban
  14. https://www.medicines.org.uk/emc/product/8842/smpc
  15. https://www.nps.org.au/medicine-finder/tirofiban-juno
  16. https://resources.schn.health.nsw.gov.au/policies/policies/pdf/2022-063.pdf
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4002824/
  18. https://www.medicines.org.uk/emc/files/pil.8842.pdf
  19. https://www.jacc.org/doi/10.1016/j.jacc.2010.10.030
  20. https://www.ahajournals.org/doi/full/10.1161/01.cir.96.5.1445
  21. https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-025-04368-1
  22. https://www.cureus.com/articles/351614-cholesterol-emboli-syndrome-following-angioplasty-a-case-report-and-literature-review
  23. https://www.sciencedirect.com/science/article/abs/pii/S2152265025028551
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7426711/
  25. https://www.drugs.com/pregnancy/tirofiban.html
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC11205062/
  27. https://pubmed.ncbi.nlm.nih.gov/32168298/
  28. https://www.frontiersin.org/journals/pediatrics/articles/10.3389/fped.2023.1138717/full
  29. https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/20912lbl.pdf
  30. https://pubmed.ncbi.nlm.nih.gov/11929319/
  31. https://www.drugs.com/monograph/tirofiban.html
  32. https://www.sciencedirect.com/science/article/pii/S0735109700011815
  33. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020912s027,020913s026lbl.pdf
  34. https://www.ncbi.nlm.nih.gov/books/NBK554376/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC2663484/
  36. https://pubmed.ncbi.nlm.nih.gov/8403299/
  37. https://www.ahajournals.org/doi/10.1161/01.cir.96.5.1445
  38. https://www.aggrastathdb.com/mechanism-of-action/
  39. https://pmc.ncbi.nlm.nih.gov/articles/PMC6563238/
  40. https://www.gloshospitals.nhs.uk/documents/2074/Tirofiban.pdf
  41. https://www.ebmconsult.com/articles/monograph-tirofiban-aggrastat
  42. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/tirofiban
  43. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fa3ac570-f9f6-474c-a920-bd0cf03045ac
  44. https://go.drugbank.com/salts/DBSALT001454
  45. https://adisinsight.springer.com/drugs/800002025
  46. https://jamanetwork.com/journals/jama/fullarticle/181767
  47. https://www.selleckchem.com/products/tirofiban.html
  48. https://pubmed.ncbi.nlm.nih.gov/12658064/
  49. https://www.dovepress.com/radiolabeled-tirofiban-ndash-a-potential-radiopharmaceutical-for-detec-peer-reviewed-fulltext-article-DDDT
  50. https://pubmed.ncbi.nlm.nih.gov/9315530/
  51. https://pubmed.ncbi.nlm.nih.gov/9599104/
  52. https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2010/02/23/19/13/PRISMPLUS
  53. https://www.ahajournals.org/doi/10.1161/01.cir.101.6.e76
  54. https://www.medscape.com/viewarticle/785151
  55. https://www.jacc.org/doi/10.1016/j.jcin.2016.05.031
  56. https://www.nejm.org/doi/full/10.1056/NEJM199805213382102
  57. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20913ltr.pdf
  58. https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/20912S001_Aggrastat.cfm
  59. https://www.ema.europa.eu/en/medicines/human/referrals/aggrastat
  60. https://www.bioworld.com/articles/545232-health-canada-approves-aggrastat-for-management-of-unstable-angina
  61. https://www.tga.gov.au/resources/artg/65162
  62. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/020912Orig1s019%2Cs020ltr.pdf
  63. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/206888Orig1s000ltr.pdf
Add your contribution
Related Hubs
User Avatar
No comments yet.